Catalytic inhibition of human DNA topoisomerase by phenolic compounds in Ardisia compressa extracts and their effect on human colon cancer cells.
Plant polyphenols, as those present in teas, have been associated with several health benefits. In this study, the main objectives were to identify and characterize the phenolic compounds in Ardisia compressa tea (AC) responsible for topoisomerase inhibition using a bioassay directed approach and modern analytical techniques, and to determine the cytotoxicity against human colon carcinoma cells. Inhibition of topoisomerase was determined by yeast and human topoisomerase biochemical assays. Identification and characterization of AC phenolic compounds were carried out using combined HPLC, MS and NMR techniques. Cytotoxicity studies were conducted using two human colorectal adenocarcinoma cell lines, HT-29 and Caco-2. LC-MS analysis of AC confirmed the presence of gallic acid, epicatechin gallate, several proanthocyanidin dimers, kaempferol, naringenin and ardisin derivatives. Topoisomerase II catalytic inhibitory activity of AC was due mainly to phenolic compounds extracted in the butanolic fraction (IC50: 1.33 microg/ml). Purification of this fraction resulted in the isolation of several compounds: peak 10 (IC50: 8.32 microg/ml), peaks 12/14 (IC75: 2.85 microg/ml) and peak 15 (IC50: 7.16 microg/ml). Characterization of peak 15, the most active fraction, led to the isolation of a naringenin isomer (C15H12O5), which had a significantly higher catalytic anti-topoisomerase II activity (IC50: 7.16 microg/ml) than commercial naringenin (IC50: 88.1 microg/ml). AC was cytotoxic to HT-29 (IC50: 57.9+/-11.6 microg/ml) and Caco-2 cells (IC50: 81.0+/-27.5 microg/ml). These findings provide basic information and suggest the potential use of active flavonoids in Ardisia compressa tea as chemopreventive agents.
Department of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign, 228 ERML, MC-051, 1201 W. Gregory Drive, Urbana, IL 61801, USA. edemejia@uiuc.edu
Elvira González
EG
de Mejía
Sonia
S
Chandra
MarcoVinicio
M
Ramírez-Mares
Wenyi
W
Wang
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D031644:Ardisia / Q000737:chemistry*; D018938:Caco-2 Cells; D049109:Cell Proliferation / Q000187:drug effects; D002849:Chromatography, Gas; D002851:Chromatography, High Pressure Liquid; D002855:Chromatography, Thin Layer; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005419:Flavonoids / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D019073:HT29 Cells; D006801:Humans; D020128:Inhibitory Concentration 50; D019906:Nuclear Magnetic Resonance, Biomolecular; D010636:Phenols / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D018515:Plant Leaves / Q000737:chemistry; D059808:Polyphenols; D021241:Spectrometry, Mass, Electrospray Ionization; D059005:Topoisomerase II Inhibitors
D005419:Flavonoids; D010636:Phenols; D059808:Polyphenols; D059005:Topoisomerase II Inhibitors